The latest addition to RCC’s Mood line melts stress & lifts your spirits Rare Cannabinoid Company (RCC) takes your mood as seriously as you do. They’re constantly on the front lines of innovation, creating products using exciting blends of hemp cannabinoids that can help relieve stress and help you find your joy. The Hawaiian brand […]

The post We tried Rare Cannabinoid Company’s THC+CBC Mood Oil appeared first on Leafly.

The post We tried Rare Cannabinoid Company’s THC+CBC Mood Oil appeared first on Paradise Found.

New THC+CBC Mood Mints from Rare Cannabinoid Company bring on mood-boosting effects quickly thanks to nanoemulsification.

The post How nano THC+CBC Mood Mints provide a fast-acting boost appeared first on Leafly.

The post How nano THC+CBC Mood Mints provide a fast-acting boost appeared first on Paradise Found.

Researchers from Romania published the results of a study in the International Journal of Molecular Sciences exploring and analyzing the effects of various phytocannabinoids and terpenes working together.

Phytocannabinoids include any naturally occurring cannabinoid found in the plant, from the more commonly known THC, and CBD to less known CBC, CBG, CBN, and more. Researchers wrote that over 100 cannabinoids have been identified in the plant. “The complex interaction between phytocannabinoids and biological systems offers hope for novel treatment approaches and lays the groundwork for further developments in the field of cannabinoid-based medicine,” the study abstract explained. “This review summarizes the state of the field, points out information gaps, and emphasizes the need for more studies to fully realize the therapeutic potential of phytocannabinoids.”

Researchers explored the entourage effect, which is the combination of both cannabinoids and terpenes working together to create effects that “exceed the sum of their separate contributions.” While consuming a product with a single cannabinoid has its benefits, consuming more than one cannabinoid or terpene together can produce even stronger, more beneficial effects. “This synergy emphasizes how important it is to consider the entire plant when utilizing cannabis medicinally as opposed to just concentrating on individual cannabinoids,” researchers explained.

Researchers also briefly wrote about terpenes, which make up the aroma and flavor of various cannabis strains. “Standardizing the terpene profile helps maintain consistency in sensory attributes and may also impact the ‘entourage’ effect—the synergistic interaction between cannabinoids and terpenes.”

The study primarily reviewed the known effects and properties of various cannabinoids, many of which offer varying levels of benefit for anti-inflammatory effects, antioxidant effects, pain management, neurological disorders, psychiatric conditions, cancer treatment support, and more. “The exploration of novel phytocannabinoids is rapidly evolving, offering exciting prospects for future therapeutic applications,” researchers wrote. “Beyond well-established compounds like THC and CBD, the quest for novel cannabinoids widens the scope of potential treatments. Each cannabinoid, with its unique chemical structure, interacts differently with the ECS, suggesting tailored therapeutic effects for specific conditions. This exploration seeks to harness similar benefits while circumventing associated drawbacks.”

The study cited examples of THC having analgesic effects and has been found to help patients treat chronic pain, while CBD has been studied for its anti-inflammatory properties and is an anxiolytic, which has potential to reduce anxiety and stress.

CBG interacts with the body’s endocannabinoid system (specifically the CB1 and CB2 receptors) in a way that suggests it can “modulate the effects of other cannabinoids by influencing CB1 receptor activity.” It has also been studied for its anticancer properties. Similar breakdowns were provided for CBC, CBN, and THCV as well.

This research is the combined presentation from 99 sources to exhibit the benefits of cannabinoids, but spotlights the complex challenges regarding the legal status of cannabis in the U.S. and the EU. However, researchers noted that these laws and regulations are subject to change as more evidence is presented.

Researchers also added that at least in the U.S., more evidence will lead to an expansion in FDA approved products. Currently, only two products—Sativex^® (which contains both CBD and THC) and Epidiolex^® (which contains only CBD)—have been approved so far. Sativex^® was approved in 2010, while Epidiolex^® was approved in 2018. “CBD and THC should be accessible to patients with special prescriptions due to their potential benefits, especially for individuals with epilepsy refractory to other medications.”

Not all countries in Europe have access to Sativex^® and/or Epidiolex^®, which has led to an increase in a reliance on obtaining cannabis products online, and also increases the risk of illegal products that are not being tested for impurities and other harmful contaminants. Due to this, researchers recommended that cannabis products should be made available as a prescription to “lower addiction risk.” “Prescription retention in pharmacies after each refill or release can aid in monitoring usage,” researchers wrote. “Additionally, THC products should adhere to state-specific rules, potentially requiring a special prescription to curb misuse.”

In their conclusion, researchers summarized the many beneficial properties of phytocannabinoids and the need for more research. “By leveraging the synergistic effects of combination therapies and targeting multiple disease pathways, phytocannabinoids hold immense potential to revolutionize the future of pharmacotherapy and improve human health outcomes,” researchers said. “However, further research, regulatory clarity, and standardized protocols are needed to fully unlock their therapeutic benefits and ensure safe and effective use in clinical practice.”

Other researchers have presented similar evidence as well, such as one study published in October 2023. A study conducted by Zentrela and PAX showed evidence of the entourage effect (in this case, the application of multiple cannabinoids and terpenes) led to two times the psychoactive effects in comparison to participants who consumed just products with high levels of delta-9 THC.

Similar evidence has been found on mushrooms as well. A study published in February in the journal Molecular Psychiatry explained how full-spectrum psilocybin extract offers superior benefits compared to synthetic psilocybin. “This research not only underscores the superiority of extracts with diverse compounds but also highlights the feasibility of incorporating them into Western medicine due to the controlled nature of mushroom cultivation,” researchers wrote in a press release.

The post Study: Researchers Present Benefits of Entourage Effect first appeared on High Times.

The post Study: Researchers Present Benefits of Entourage Effect appeared first on Paradise Found.

Looking for recommendations on the hottest 1:1 THC to CBD ratio seeds, autoflowers, mixed ratios and beyond? We’ve got you covered.

The post The best balanced CBD:THC weed seeds in 2024 appeared first on Leafly.

The post The best balanced CBD:THC weed seeds in 2024 appeared first on Paradise Found.

Rare cannabinoid gummies from Rare Cannabinoid Company now include options both with and without delta-9 THC.

The post Rare cannabinoid gummies get a buzzy upgrade, featuring new options with and without delta-9 THC appeared first on Leafly.

The post Rare cannabinoid gummies get a buzzy upgrade, featuring new options with and without delta-9 THC appeared first on Paradise Found.

Higher Dayz THC+CBC edibles, vapes, and infused pre-rolls offer a unique and differentiated high for elevating the day with friends.

The post Seize the day and take it higher with Spinach FEELZ^™ Higher Dayz THC+CBC appeared first on Leafly.

The post Seize the day and take it higher with Spinach FEELZ™ Higher Dayz THC+CBC appeared first on Paradise Found.

Read about the experience & try a free pack of delta-9 THC + CBC Mood Gummies from Rare Cannabinoid Company.

The post We tried delta-9 THC + CBC Mood Gummies with Rare Cannabinoid Company appeared first on Leafly.

The post We tried delta-9 THC + CBC Mood Gummies with Rare Cannabinoid Company appeared first on Paradise Found.

Raphael Mechoulam, the first person to synthesize THC, earning him the moniker the “Father of Cannabis Science,” has died, Analytical Cannabis reports. He was 92 years old, and his legacy will most certainly live on for centuries to come. The esteemed chemist is also called the father of cannabis research. Some of his additional game-changing contributions to drug science include isolating and synthesizing other cannabinoids, such as cannabidiol (CBD), cannabigerol (CBG), and cannabichromene (CBC). 

While THC, CBD, and CBG are basically household names today, that would not be the case if it weren’t for Dr. Mechoulam, so smoke one out for him in remembrance. A medicinal chemistry professor at the Hebrew University of Jerusalem in Israel, his work laid the groundwork and got the ball (or blunt) rolling to prompt future breakthroughs, such as illumination into the human body’s internal cannabinoid receptors in the 1980s and ’90s, as detailed in the 1993 academic paper titled Molecular characterization of a peripheral receptor for cannabinoids. 

Make sure to pay your respects today, as Dr. Mechoulam’s friends and fellow scientists are, as you pass the peace pipe around with your buddies. “This is a very sad day for me, for the science community and for the cannabis community. Professor Raphael Mechoulam or as we called him Raphi, was one of the greatest scientist[s] I ever met and was my teacher and mentor in many aspects. I truly believe he [deserved] a Nobel prize!” wrote David “Dedi” Meiri, an associate professor at Technion, the Israel Institute of Technology, and one Mechoulam’s colleagues, in a touching online statement. “Thank you Raphi for all the great things you did and discover[ed] in your life and thanks for all the help and support you gave me. Rest in peace my dear friend,” he continues. 

Born in Sofia, Bulgaria, in 1930, Mechoulam and his family relocated to Israel, where he began studying chemistry. His inspiration to start his successful hunt for THC began after wise observance of other drugs’ mechanisms. In an interview with CNN in 2014, Mechoulam pointed out that: “Morphine had been isolated from opium in the nineteenth century, early nineteenth century, cocaine had been isolated from coca leaves [in the] mid-nineteenth century. And here we were, mid-twentieth century, and yet the chemistry of cannabis was not known. So it looked like [an] interesting project.” According to the National Library of Medicine, in 1964, he succeeded. And the story behind how Mechoulam obtained the cannabis he studied may surprise you. 

While working as a chemist in the early 1960s at the Weizmann Institute, Mechoulam got some weed from the Israeli police with his goal already in place: to discover and isolate what makes pot psychoactive. Once THC and other cannabinoids, such as the aforementioned CBD and CBG, were identified, in 1992, Mechoulam and his team discovered the chemical arachidonoyl ethanolamine, which you know as anandamide (derived from the Sanskrit word ananda, which means bliss). Anandamide is something our body’s endocannabinoid system produces on its own (as if we are built to use cannabis) and activates the CB1 receptor. 

Deeply passionate and hardworking, Mechoulam continued his research right up to his death. At the age of 88, at the cannabis conference CannMed in California in 2019, he announced another breakthrough, synthetically stable cannabidiolic acid (CBDA), the main phytocannabinoid in fiber and seed-oil hemp, which contains anti-inflammatory, anti-convulsant, and anti-cancerogenic properties, and that’s likely just the tip of the iceberg. “We have taken the unstable acid molecules of the cannabis plant and synthesized them to provide a stable, consistent basis for researching new therapies across a wide range of medical needs,” Mechoulam explained at the conference. He also used his stage time to encourage the scientific community to invest more into cannabis research, as enough time has already been lost, citing the many people from the past who would have vastly benefited from medicinal cannabis should it have been available. “Did we have to wait 30 years? No,” he said. “We could have helped thousands of children, and we didn’t.” 

Rest in Power, Dr. Mechoulam, and may everyone lucky enough to have access to the results of his work enjoy the power of plant medicine today. 

The post ‘Father of Cannabis Science’ Raphael Mechoulam Dead at 92 appeared first on High Times.

The post ‘Father of Cannabis Science’ Raphael Mechoulam Dead at 92 appeared first on Paradise Found.

New mood-boosting gummies from Rare Cannabinoid Company contain 5mg delta-9 THC+CBC in high levels. Learn about how the formula works.

The post Rare Cannabinoid Company launches new delta-9 THC+CBC mood gummies appeared first on Leafly.

The post Rare Cannabinoid Company launches new delta-9 THC+CBC mood gummies appeared first on Paradise Found.

Rare Cannabinoid Company’s apothecary lets you to build your own blend from the base up so you can fine-tune your cannabinoid intake to meet your needs.

The post Cannabis deconstructed: Create your own custom blend with Rare Cannabinoid Company’s apothecary appeared first on Leafly.

The post Cannabis deconstructed: Create your own custom blend with Rare Cannabinoid Company’s apothecary appeared first on Paradise Found.